Marker Therapeutics, Inc. (MRKR)
1.45
-0.01
(-0.68%)
USD |
NASDAQ |
May 07, 15:29
Marker Therapeutics Cash from Financing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Tenaya Therapeutics, Inc. | 58.24M |
| ACADIA Pharmaceuticals, Inc. | 22.67M |
| Neurocrine Biosciences, Inc. | -86.10M |
| Viridian Therapeutics, Inc. | 6.357M |
| electroCore, Inc. | -0.04M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.900M |
| Free Cash Flow | -12.01M |
| Free Cash Flow Per Share (Quarterly) | -0.114 |
| Free Cash Flow to Equity (Quarterly) | -1.900M |
| Free Cash Flow to Firm (Quarterly) | -1.900M |
| Free Cash Flow Yield | -56.66% |